EUVIMEDEUVIMED entdecken
Open Access

Visualizing Baseline Eligibility Across Locally Advanced or Metastatic Urothelial Cancer Trials and Real‐World Cohorts

Takaki Ichiyama, Takuma Narita iD, Hiroyuki Sato, Yuya Sekine, Masanao Shinohara, Yohei Kawashima, Mizuki Kobayashi iD, Kazuyuki Numakura iD, Jotaro Mikami, Naoki Fujita iD, Teppei Okamoto iD, Hayato Yamamoto iD und 6 weitere

International Journal of Urology · 2026

DOI: 10.1111/iju.70598 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, 2026. Verfasst von Takaki Ichiyama und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Clinical Trials as Topic, Patient Selection, Urologic Neoplasms. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical trials in locally advanced or metastatic urothelial carcinoma (mUC) often enroll younger and fitter patients than those treated in routine practice, limiting applicability to real‐world populations. We developed a simple descriptive metric, the eligibility gap (EG) score, to place trial and real‐world cohorts on a common scale and summarize differences in baseline eligibility profiles.

Methods

Pivotal clinical trials were identified through a PubMed search, and three real‐world datasets from Japan, the United States, and Spain were included. The EG score used three consistently reported domains: age, ECOG performance status, and cisplatin eligibility. Each domain was scaled from 0 to 33.3 points and summed to yield a score from 0 to 99.9, with higher scores indicating younger, fitter populations. Robustness was assessed across alternative model specifications, including prespecified weighting schemes, random‐weight simulations, alternative age and ECOG scoring functions, and one‐domain‐out analyses.

Results

EG scores were generally higher in cisplatin‐based trials (74.8–90.1) than in immune checkpoint inhibitors (ICI)‐based trials (52.3–81.2) and real‐world cohorts (35.1–45.5), while the cisplatin‐ineligible trial had the lowest score (24.5). Alternative age transformations and a linear ECOG model did not change ranking. In one‐domain‐out analyses, omission of ECOG preserved ranking, whereas omission of age or cisplatin‐fitness produced minor shifts. Across prespecified weighting schemes, rank‐order concordance remained high (Spearman's rho = 0.982–1.000), and 10 000 random‐weight simulations showed a median rho of 0.982.

Conclusions

The EG score may provide a simple descriptive summary of eligibility domains across mUC studies, with stable cohort ordering across alternative model specifications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Transitional CellClinical Trials as TopicPatient SelectionUrologic NeoplasmsEligibility DeterminationHumansCisplatinNeoplasm MetastasisAge FactorsImmune Checkpoint InhibitorsJapan

Stichwörter der Autor:innen

eligibilitymetastaticreal‐worldtrial representativenessurothelial carcinoma

Substanzen

CisplatinImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
  • Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.
  • Department of Urology, Ageo Central General Hospital, Ageo, Japan.
  • Department of Renal and Urologic Surgery, Asahikawa Medical University, Asahikawa, Japan.
  • Department of Urology, Tsugaru General Hospital, Goshogawara, Japan.
  • Japanese Red Cross Osaka Hospital, Osaka, Japan.

ORCID-Profile: Takuma Narita, Mizuki Kobayashi, Kazuyuki Numakura, Naoki Fujita, Teppei Okamoto, Hayato Yamamoto, Shintaro Narita, Shingo Hatakeyama

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Ichiyama, T., Narita, T., Sato, H., Sekine, Y., Shinohara, M., Kawashima, Y., Kobayashi, M., Numakura, K., Mikami, J., Fujita, N., Okamoto, T., Yamamoto, H., Yoneyama, T., Narita, S., Sato, S., Habuchi, T., Ohyama, C., & Hatakeyama, S. (2026). Visualizing Baseline Eligibility Across Locally Advanced or Metastatic Urothelial Cancer Trials and Real‐World Cohorts. International Journal of Urology. https://doi.org/10.1111/iju.70598

Vancouver

Ichiyama T, Narita T, Sato H, Sekine Y, Shinohara M, Kawashima Y, et al. Visualizing Baseline Eligibility Across Locally Advanced or Metastatic Urothelial Cancer Trials and Real‐World Cohorts. International Journal of Urology. 2026. doi:10.1111/iju.70598

BibTeX
@article{Ichiyama2026,
  author = {Ichiyama, Takaki and Narita, Takuma and Sato, Hiroyuki and Sekine, Yuya and Shinohara, Masanao and Kawashima, Yohei and Kobayashi, Mizuki and Numakura, Kazuyuki and Mikami, Jotaro and Fujita, Naoki and Okamoto, Teppei and Yamamoto, Hayato and Yoneyama, Takahiro and Narita, Shintaro and Sato, Satoshi and Habuchi, Tomonori and Ohyama, Chikara and Hatakeyama, Shingo},
  title = {Visualizing Baseline Eligibility Across Locally Advanced or Metastatic Urothelial Cancer Trials and Real‐World Cohorts},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70598}
}
Kostenlos starten →